CRC patients with high-grade tumors (n = 4) had significantly higher levels of circulating CD33+, CD33+CD11b+, and CD33+CD11b+HLA-DR−/low cells compared with HDs (n = 21) and patients with low-grade tumors (n = 16). The gene discussed is CD33; the disease is colorectal carcinoma.